240 related articles for article (PubMed ID: 36199692)
1. A bibliometric research based on hotspots and frontier trends of denosumab.
Ren B; Ren X; Wang L; Tu C; Zhang W; Liu Z; Qi L; Wan L; Pang K; Tao C; Li Z
Front Pharmacol; 2022; 13():929223. PubMed ID: 36199692
[TBL] [Abstract][Full Text] [Related]
2. Denosumab for giant cell tumors of bone from 2010 to 2022: a bibliometric analysis.
Tan X; Zhang Y; Wei D; Yang Y; Xiang F
Clin Exp Med; 2023 Nov; 23(7):3053-3075. PubMed ID: 37103655
[TBL] [Abstract][Full Text] [Related]
3. Investigating Research Hotspots and Publication Trends of Spinal Stenosis: A Bibliometric Analysis During 2000-2018.
Yang K; Pei L; Wen K; Zhou S; Tao L
Front Med (Lausanne); 2021; 8():556022. PubMed ID: 34354999
[TBL] [Abstract][Full Text] [Related]
4. Global trends and hotspots on childhood obstructive sleep apnea: a 10-year bibliometric analysis.
Wang C; Sun K; Zhang S; Hu H; Lu Y; Liu K; Yu Z
Front Pediatr; 2023; 11():1160396. PubMed ID: 37234857
[TBL] [Abstract][Full Text] [Related]
5. Research hotspots and trends analysis of ankylosing spondylitis: a bibliometric and scientometric analysis from 2009 to 2018.
Liang M; Meng Y; Zhou S; Tao Z; Tao L
Ann Transl Med; 2020 Nov; 8(21):1445. PubMed ID: 33313190
[TBL] [Abstract][Full Text] [Related]
6. The publication trends and hot spots of scoliosis research from 2009 to 2018: a 10-year bibliometric analysis.
Tao L; Zhou S; Tao Z; Wen K; Da W; Meng Y; Zhu Y
Ann Transl Med; 2020 Mar; 8(6):365. PubMed ID: 32355809
[TBL] [Abstract][Full Text] [Related]
7. Mapping theme trends and recognizing hot spots in postmenopausal osteoporosis research: a bibliometric analysis.
Zhou S; Tao Z; Zhu Y; Tao L
PeerJ; 2019; 7():e8145. PubMed ID: 31788368
[TBL] [Abstract][Full Text] [Related]
8. Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.
Cadieux B; Coleman R; Jafarinasabian P; Lipton A; Orlowski RZ; Saad F; Scagliotti GV; Shimizu K; Stopeck A
J Bone Oncol; 2022 Apr; 33():100416. PubMed ID: 35242510
[TBL] [Abstract][Full Text] [Related]
9. Trends of denosumab-related publications in web of science.
Jiang X; Xie T; Feng W; Qin Z; Liao S; Liu Y; Lu S; He M; Wei Q
Medicine (Baltimore); 2023 Jan; 102(4):e32784. PubMed ID: 36705356
[TBL] [Abstract][Full Text] [Related]
10. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.
Brown-Glaberman U; Stopeck AT
Biologics; 2012; 6():89-99. PubMed ID: 22532777
[TBL] [Abstract][Full Text] [Related]
11. Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials.
Lu J; Hu D; Zhang Y; Ma C; Shen L; Shuai B
Front Oncol; 2023; 13():1133828. PubMed ID: 36860316
[TBL] [Abstract][Full Text] [Related]
12. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
Varenna M; Gatti D
Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
[TBL] [Abstract][Full Text] [Related]
13. Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy.
Zhang N; Zhang ZK; Yu Y; Zhuo Z; Zhang G; Zhang BT
Front Cell Dev Biol; 2020; 8():325. PubMed ID: 32478071
[TBL] [Abstract][Full Text] [Related]
14. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
[TBL] [Abstract][Full Text] [Related]
15. [Updates of denosumab, anti-RANKL antibody for osteoporosis].
Tokuyama N; Tanaka S
Clin Calcium; 2014 Jan; 24(1):85-91. PubMed ID: 24369284
[TBL] [Abstract][Full Text] [Related]
16. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review.
Bridgeman MB; Pathak R
Clin Ther; 2011 Nov; 33(11):1547-59. PubMed ID: 22108301
[TBL] [Abstract][Full Text] [Related]
17. A review of denosumab for the treatment of osteoporosis.
Miyazaki T; Tokimura F; Tanaka S
Patient Prefer Adherence; 2014; 8():463-71. PubMed ID: 24748775
[TBL] [Abstract][Full Text] [Related]
18. Can denosumab be a substitute, competitor, or complement to bisphosphonates?
Kim SY; Ok HG; Birkenmaier C; Kim KH
Korean J Pain; 2017 Apr; 30(2):86-92. PubMed ID: 28416991
[TBL] [Abstract][Full Text] [Related]
19. Research hotspots and trends in internal fixation of femoral neck fractures from 2010 to 2022: A 12-year bibliometric analysis.
Ling W; Chen L
Medicine (Baltimore); 2023 Jun; 102(23):e34003. PubMed ID: 37335643
[TBL] [Abstract][Full Text] [Related]
20. Mapping Knowledge Landscapes and Emerging Trends of the Links Between Bone Metabolism and Diabetes Mellitus: A Bibliometric Analysis From 2000 to 2021.
Cheng K; Guo Q; Yang W; Wang Y; Sun Z; Wu H
Front Public Health; 2022; 10():918483. PubMed ID: 35719662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
